Announcement under Regulation 30 (LODR)-Investor Presentation

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be participating in 'Edelweiss India Conference, 2022, Singapore' physical Investor meetings to be held on Thursday, August 18, 2022 and Friday, August 19, 2022 in Singapore. The details of the Investors are mentioned in ....

about 1 month ago

INVESTOR PRESENTATION

Tweet

Sentiments detected

Positive 139
  • Augmented capacity of Pyridine & Picolines 40+ years leadership in in Nira, MH plant (60 KTA) Chemical Intermediate 2008.

  • Consumption Japan - leading to sustainable revenue

  • Strong Corporate Vision to double Agro 22% step chemistries Governance, the Revenue by Offices in India, US, Europe, Japan Nutrition (Up to~13 steps)

  • Fermentation Esterification Quarternisation Ethylene Oxide Chiral Chlorination / Reaction N-Formylation Synthesis Photo chlorination Ketene Technology Hydrogenation Chichibabin De-alkylation Optimization Existing product’s processes to remain globally competitive Expansion

  • Key focus areas for RDT Academic Collaboration New technologies by academia collaboration/expanding internal infrastructure Scientific Advisory Strong Scientific advisory board to support RDT Board Centre of Excellence For Bio catalysis, Flow chemistry, Chemo catalysis, Gas phase Catalytic Chemistry 10

  • “We are glad to announce steady operational and financial performance in Q1’FY23, in the backdrop of inflationary headwinds leading to higher raw material and energy costs during the quarter.

  • In our Specialty Chemicals Business revenue grew 26% YoY, on account of strong demand across all our product segments.

  • This is a short-term challenge in the segment, and business continues to maintain its market share and leadership position.

  • Our Chemical Intermediates Business, continue to witness strong demand resulting into volume growth.

  • Business is maintaining the leadership position of Acetic Anhydride in Domestic market and also Improving our market share in Europe.

  • On YoY basis segment has witnessed normalization of market situation and lower Acetic Acid prices, which is also reflecting into both Revenue and EBITDA.

  • We are fully committed towards our growth aspirations and we are excited to realise the emerging opportunities going forward in all our business segments.

  • We are fully confident of moving ahead with our well defined growth capex plan , which is supported by our internal accruals.

  • Our aim is to achieve sustainable profitable growth in medium term and structurally we are poised towards moving on to the next tier of performance in our growth journey and margins”.

  • Overall Revenue grew by 2% on YoY basis, mainly due to higher sales Speciality Chemicals 39.5 49.6 26% Nutrition & Health Solutions 21.6 19.5 (10%) performance by Speciality Chemical Business.

  • Speciality Chemicals revenue grew by 26% YoY driven by volume Total Revenue from Operations 148.3 151.1 2% growth across product segments Reported EBITDA 37.2 19.6 (47%) •

  • Chemical Intermediates volume have grown while revenue is EPS 0.14 0.06 (53%) Reported EBITDA Margins 25.1% 12.9% impacted mainly due to lower prices of key RM i.e. Acetic Acid.

  • Overall Revenue grew by 2% on YoY basis, mainly due to higher sales Nutrition & Health Solutions 167 150 (10%) performance by Speciality Chemical Business.

  • Speciality Chemicals revenue grew by 26% YoY driven by volume Total Revenue from Operations 1,145 1,166 2% growth across product segments Reported EBITDA 287 151 (47%) •

  • (58%) segment, and business continues to maintain its market share and Unallocated Corporate (Expenses)/Income -7 -8 -

  • Revenue grew by 42% on YoY basis, driven by growth across Business Nutrition & Health Solutions 81.6 99.4 22% segments.

  • Speciality Chemicals revenue grew by 24% YoY driven by volume and Total Revenue from Operations 452.3 641.3 42% price growth across products.

  • Reported EBITDA 81.2 111.9 38% - Speciality Chemical Volume grew by 16% on YoY basis.

  • Speciality Chemicals 34.8 40.5 16% • Nutrition and Health Solutions revenue grew by 22% YoY driven by Nutrition & Health Solutions 16.9 21.3 26% higher volumes and as well as higher prices.

  • Chemical Intermediates 30.6 54.0 77% - Niacinamide volume grew by 9% on YoY basis.

  • Chemical Intermediates revenue grew by 61% YoY, Overall driven by PAT 41.0 61.8 51% higher prices and favorable market conditions, during the majority EPS 0.3 0.4 51% part of the financial year.

  • Reported EBITDA Margins 17.9% 17.4% - Acetic Anhydride Volume grew by 3% on YoY basis.

  • Speciality Chemicals 23.9% 22.4% - EBITDA at USD 111.9 Million, grew by 38% on account of strong Nutrition & Health Solutions 20.7% 21.4% Chemical Intermediates 13.6% 14.9% performance of all the three product segments.

  • PAT grew by 51% YoY driven by growth in EBITDA, aided by reduction in finance cost on account of reduction in Debt and optimization of FY22 Geographical Revenue Split FY22 Industry End-Use Split Interest rates.

  • Domestic Sales for Consumer 3% - ROCE in FY22 improved to 27.8 % against 20.2% in FY21 5% RoW International • ROE in FY22 stood at 21.9% as against 16.4% in FY21. 10% Consumption 17% Industrial 18% Pharma Europe 37% 1.

  • FINANCIALHIGHLIGHTS Revenue Speciality Chemicals 1,124 1,393 24% • Revenue grew by 42% on YoY basis, driven by growth across Business Nutrition & Health Solutions 630 767 22% segments.

  • Chemical Intermediates 1,738 2,789 61% - Speciality Chemicals revenue grew by 24% YoY driven by volume and Total Revenue from Operations 3,491 4,949 42% price growth across products.

  • Reported EBITDA 627 863 38% - Speciality Chemical Volume grew by 16% on YoY basis.

  • Speciality Chemicals 268 312 16% • Nutrition and Health Solutions revenue grew by 22% YoY driven by Nutrition & Health Solutions 130 164 26% higher volumes and as well as higher prices.

  • Chemical Intermediates 236 417 77% - Niacinamide volume grew by 9% on YoY basis.

  • Chemical Intermediates revenue grew by 61% YoY, Overall driven by PAT 316 477 51% higher prices and favorable market conditions, during the majority EPS 19.9 30.0 51% Reported EBITDA Margins 17.9% 17.4% part of the financial year.

  • Speciality Chemicals 23.9% 22.4% - Acetic Anhydride Volume grew by 3% on YoY basis.

  • Nutrition & Health Solutions 20.7% 21.4% - EBITDA at Rs 863 Crore, grew by 38% on account of strong Chemical Intermediates 13.6% 14.9% performance of all the three product segments.

  • Net Margin 9.1% 9.6% - PAT grew by 51% YoY driven by growth in EBITDA, aided by reduction in finance cost on account of reduction in Debt and optimization of FY22 Geographical Revenue Split FY22 Industry End-Use Split

  • Domestic Sales for Consumer 3% - ROCE in FY22 improved to 27.8 % against 20.2% in FY21 5% RoW International • ROE in FY22 stood at 21.9% as against 16.4% in FY21. 10% Consumption 17% Industrial 18% Pharma Europe 37% 1.

  •  CRISIL Ratings has revised its outlook on the long-term Debt of Jubilant Ingrevia Ltd to now ‘Positive’ from earlier ‘Stable’, while reaffirming the rating at ‘CRISIL AA’ in May’22.

  •  CRISIL Ratings has revised its outlook on the long-term Debt of Jubilant Ingrevia Ltd to now ‘Positive’ from earlier ‘Stable’, while reaffirming the rating at ‘CRISIL AA’ in May’22.

  • In line with our Vision to double the Revenue by FY’26, we have 36 29% Products in Pipeline.

  • Revenue 39.5 49.6 26%  Specialty Chemicals revenue grew by 26% on YoY basis driven by Reported EBITDA 10.9 8.3 (24%) higher volume across product segments Reported EBITDA Margin (%) 27.7% 16.8%  Specialty Volumes grew by 24% YOY basis  Share of revenue to customers having Agro Chemical end use grew significantly.

  •  We also witnessed healthy demand for Oil field chemicals.

  • Domestic Sales  Signed a CDMO contract worth Rs.270

  • Consumption 8% 30%  Our CDMO Pipeline is healthy and progressing positively.

  • GMP and non-GMP facilities which are expected to be ready during Q3FY’23, will help us in capture growing demand of CDMO projects.

  • We observed positive traction of demand for our other Specialty chemicals also from both domestic as well as international 1.

  • Revenue 305 382 26%  Specialty Chemicals revenue grew by 26% on YoY basis driven by Reported EBITDA 84 64 (24%) higher volume across product segments Reported EBITDA Margin (%) 27.7% 16.8%  Specialty Volumes grew by 24% YOY basis  Share of revenue to customers having Agro Chemical end use grew significantly.

  •  We also witnessed healthy demand for Oil field chemicals.

  • Domestic Sales  Signed a CDMO contract worth Rs.270

  • Consumption 8% 30%  Our CDMO Pipeline is healthy and progressing positively.

  • GMP and non-GMP facilities which are expected to be ready during Q3FY’23, will help us in capture growing demand of CDMO projects.

  • We observed positive traction of demand for our other Specialty chemicals also from both domestic as well as international 1.

  • FINANCIALHIGHLIGHTS Revenue 145.6 180.4 24%  Specialty Chemicals revenue grew by 24% on YoY Reported EBITDA 34.8 40.5 16% basis driven by higher volume across products and Reported EBITDA Margin (%) 23.9% 22.4% new launches.

  • Products Volume Growth FY'22  Domestic revenue grew significantly, by 35%

  • Specialty Chemical 16.0% percentage share to total revenue increased to 32% from 27% during previous year

  • FY22 Geographical Revenue Split FY22 Industry End-Use Split  Revenue in North American region increased by 36% Domestic Sales Nutrition, 8% on YoY. for International Consumption Consumer, 9%  Revenue from customers having Nutrition, RoW, 17% 16% consumer and Industrial end-use grew significantly Industrial, 9% Pharma, 44% on YoY basis Europe, India, 50% 26% Domestic Sales Agrochemical, EBITDA: for Domestic 29% Consumption  EBITDA grew by 16% YoY. 33% North America, 8%  EBITDA Margin were at 22.4% vs 23.9% in FY21, *Industrial include Paints & Coatings, Print & Packaging, Solvents etc. impacted due to higher raw material prices and **Consumer include Personal Care, Fragrances etc. increase in other input costs.

  • FINANCIALHIGHLIGHTS Revenue 1,124 1,393 24%  Specialty Chemicals revenue grew by 24% on YoY Reported EBITDA 268 312 16% basis driven by higher volume across products and Reported EBITDA Margin (%) 23.9% 22.4% new launches.

  • Products Volume Growth FY'22  Domestic revenue grew significantly, by 35%

  • Specialty Chemical 16.0% percentage share to total revenue increased to 32% from 27% during previous year

  • FY22 Geographical Revenue Split FY22 Industry End-Use Split  Revenue in North American region increased by 36% Domestic Sales Nutrition, 8% on YoY. for International Consumption Consumer, 9%  Revenue from customers having Nutrition, RoW, 17% 16% consumer and Industrial end-use grew significantly Industrial, 9% Pharma, 44% on YoY basis Europe, India, 50% 26% Domestic Sales Agrochemical, EBITDA: for Domestic 29% Consumption  EBITDA grew by 16% YoY. 33% North America, 8%  EBITDA Margin were at 22.4% vs 23.9% in FY21, *Industrial include Paints & Coatings, Print & Packaging, Solvents etc. impacted due to higher raw material prices and **Consumer include Personal Care, Fragrances etc. increase in other input costs.

  • Revenue Segmentation (FY’22) & Domestic leader in Vitamin 100% in-house sourcing

  • Europe, 33% Feed, 60%  Flu position in EU & America regions are improving and we expect 25% North normal demand to start during second half of the current quarter.

  • America, 19%  We improved our market share in niche segments like Food & Cosmetics on YOY Basis.

  •  Our Animal Nutrition business has witnessed strong demand in India, Business has significantly improved volume and revenue from value added Specialty premixes.

  • Business witnessed a short-term challenge but maintains its market Food, share and leadership position.

  • Europe, 33% Feed, 60%  Flu position in EU & America regions are improving and we expect 25% North normal demand to start during second half of the current quarter.

  • America, 19%  We improved our market share in niche segments like Food & Cosmetics on YOY Basis.

  •  Our Animal Nutrition business has witnessed strong demand in India, Business has significantly improved volume and revenue from value 1.

  • FINANCIALHIGHLIGHTS Revenue 81.6 99.4 22% Reported EBITDA 16.9 21.3 26%  Nutrition and Health Solutions revenue grew by 22% Reported EBITDA Margin (%) 20.7% 21.4% - on YoY basis.

  • - Growth of Vitamin Business was driven by higher Products Volume Growth FY'22 volumes and improved prices .

  • Niacinamide 9.0% - Animal Nutrition and Health solution business also improved volumes and realization YOY.

  • FY22 Industry End-Use Split  Revenue in North America and EU grew significantly Domestic Sales for by 78% and 65% respectively.

  • Domestic Consumption 24% Cosmetics, 4% Technical, 1%  Food and cosmetics revenue has gone up significantly Food, with 48% and 56% respectively.

  • Feed, 70% EBITDA North  EBITDA grew by 26% on YoY basis.

  • EBIDTA Margin Europe, 33% America, 19% stood at 21.4% , EBITDA improved on account of better realization and higher volumes .

  • FINANCIALHIGHLIGHTS Revenue 630 767 22% Reported EBITDA 130 164 26%  Nutrition and Health Solutions revenue grew by 22%

  • - Growth of Vitamin Business was driven by higher Products Volume Growth FY'22 volumes and improved prices .

  • Niacinamide 9.0% - Animal Nutrition and Health solution business also improved volumes and realization YOY.

  • FY22 Industry End-Use Split  Revenue in North America and EU grew significantly Domestic Sales for by 78% and 65% respectively.

  • Domestic Consumption 24% Cosmetics, 4% Technical, 1%  Food and cosmetics revenue has gone up significantly Food, with 48% and 56% respectively.

  • Feed, 70% EBITDA North  EBITDA grew by 26% on YoY basis.

  • EBIDTA Margin Europe, 33% America, 19% stood at 21.4% , EBITDA improved on account of better realization and higher volumes .

  • Region wise Revenue Segmentation 9 Products Acetic Anhydride: Entered Value added Globally No. 2 in derivative Propionic For Segment (FY’22) (Acetic Anhydride, Ethyl Merchant Mkt Anhydride to RoW 3%

  • Artificial Pharmaceuticals Sweeteners Agro India Pharma and Agro applications are estimated to witness strong Industrial 28% Pharma growth, mainly driven by Paracetamol, Acephate and Ibuprofen. 43%

  • Shift of manufacturing from China to India will encourage growth in Cellulose Modified Packaging & various industrial applications in India.

  • In line with our Vision to double the Revenue by FY’26, we have 7 Products in Pipeline

  •  Chemical Intermediates business continue to witness strong Reported EBITDA 23.8 9.9 (58%) demandresulting into robust volume growth.

  • Reported EBITDA Margin (%) 27.3% 12.1%  Acetic Anhydride volumes grew by 22% on YOY basis.

  •  Segment revenue de-grew by 6% on YoY basis mainly due to lower input price i.e Acetic Acid price which is now stabilizing.

  •  Revenue from Europe & Japan have gone up significantly on YoY basis.

  • EBITDA  On YoY basis segment has witnessed normalized market situation as well as lower Acetic Acid prices, which is also reflecting into both Revenue as well as EBITDA Q1’FY23

  • Domestic Sales for  We continue to maintain domestic market leadership for Acetic International Europe Consumption 19% Pharma

  •  Our market share in Europe has improved significantly and is Domestic Sales for continuing to grow.

  • India 71% Domestic Agro 25%  We are witnessing good traction of demand for our new product i.e Consumption 52% Propionic Anhydride Nutrition 5%  Our upcoming Acetic Anhydride plant at Bharuch is under construction and is expected to be ready during Q4’FY23.

  •  Chemical Intermediates business continue to witness strong Reported EBITDA 184 76

  • demandresulting into robust volume growth.

  • Reported EBITDA Margin (%) 27.3% 12.1%  Acetic Anhydride volumes grew by 22% on YOY basis.

  •  Segment revenue de-grew by 6% on YoY basis mainly due to lower input price i.e Acetic Acid price which is now stabilizing.

  •  Revenue from Europe & Japan have gone up significantly on YoY basis.

  • EBITDA  On YoY basis segment has witnessed normalized market situation as well as lower Acetic Acid prices, which is also reflecting into both Revenue as well as EBITDA Q1’FY23

  • Domestic Sales for  We continue to maintain domestic market leadership for Acetic International Europe Consumption 19% Pharma

  •  Our market share in Europe has improved significantly and is Domestic Sales for continuing to grow.

  • India 71% Domestic Agro 25%  We are witnessing good traction of demand for our new product i.e Consumption 52% Propionic Anhydride Nutrition 5%  Our upcoming Acetic Anhydride plant at Bharuch is under construction and is expected to be ready during Q4’FY23.

  • FINANCIALHIGHLIGHTS Revenue 225.1 361.4 61% Reported EBITDA 30.6 54.0 77%  Chemical Intermediates revenue grew by 61% on YoY

  • Reported EBITDA Margin (%) 13.6% 14.9% basis - Chemical Intermediates revenue growth was Products Volume Growth FY'22 driven by higher prices and volume growth in Acetic Anhydride 3.0% Acetic Anhydride.

  • Ethyl Acetate - • Prices improvement was mainly on account of favorable market condition.

  • FY22 Industry End-Use Split - Revenue from sales in EU region have gone up significantly by 130% on YoY basis.

  • RoW 3% Domestic Sales - Share of sales from EU increased to 15% for International Consumption from 11% in FY21 22% Industrial

  • North 15% Pharma  EBITDA grew by 77%.

  • Growth America 43% 0.10% in EBITDA margin was driven by India 82% Domestic Sales Agro 24%  Improved product contribution driven by for Domestic Consumption favorable market conditionsof Acetic Anhydride.

  • Nutrition 6%  Improved pricing of Ethyl Acetate also contributed to margin expansion.

  • FINANCIALHIGHLIGHTS Revenue 1,738 2,789 61%  Chemical Intermediates revenue grew by 61% on YoY Reported EBITDA 236 417 77% basis

  • Reported EBITDA Margin (%) 13.6% 14.9% - Chemical Intermediates revenue growth was Products Volume Growth FY'22 driven by higher prices and volume growth in Acetic Anhydride 3.0% Acetic Anhydride.

  • Ethyl Acetate - • Prices improvement was mainly on account of favorable market condition.

  • FY22 Industry End-Use Split - Revenue from sales in EU region have gone up significantly by 130% on YoY basis.

  • RoW 3% Domestic Sales - Share of sales from EU increased to 15% for International Consumption from 11% in FY21 22% Industrial

  • North 15% Pharma  EBITDA grew by 77%.

  • Growth America 43% 0.10% in EBITDA margin was driven by India 82% Domestic Sales Agro 24%  Improved product contribution driven by for Domestic Consumption favorable market conditionsof Acetic Anhydride.

  • Nutrition 6%  Improved pricing of Ethyl Acetate also contributed to margin expansion.

  • Outlook | As on 30 th June, 2022  We expect overall healthy revenue growth during FY’23, led by volume growth in Specialty Chemicals & Chemical intermediate business segment.

  • Commissioning of our three new capex of CDMO GMP, CDMO non-GMP and Acetic Anhydride is likely to aid the revenue growth.

  • In the Nutrition & Health Solution segment Niacinamide demand is expected to start normalizing in the later part of the current quarter  We expect our EBIDTA of subsequent quarters of FY’23 to improve, assuming no unexpected adverse situation  We are fully committed towards our growth aspirations and we are excited to realise the emerging opportunities through our ongoing Growth Capex plan of Rs 2,050 Crore / USD 265.6 Mn during FY’22 to FY’25 Period.

  •  We are strategizing towards improving our revenue mix of Specialty and Nutrition segments to 65% by FY’26 from 46% in FY’22 and we believe this to be a key driver for overall margin improvements.

  • FY’24 & FY’25) Intended to be funded through internal accruals # Expected Peak Revenue of USD 246.2 Million # Expected Peak Revenue of USD 336.9 Million From USD 116.1 Million Investment From USD 149.0 Million Crore Investment

  • Crores From Rs. 900 Crore Investment

  • Speciality & Nutrition will be 65% of Revenue up from present 46% post commissioning of our announced growth capex plans Revenue in INR Crores at Base price of FY’21 Speciality, Nutrition & Others: 65% Acetyls: 35% Speciality, Nutrition & Others: 52% Acetyls: 48% Speciality, Nutrition & Others: 46% Acetyls: 54% 1,230.9 894.0 640.6 FY'22 # Expected Peak Revenue with Committed Growth # Expected Peak Revenue with Capex of USD.

  • In addition to this we would also have growth in revenue from existing facilities.

  • Speciality & Nutrition will be 65% of Revenue up from present 46% post commissioning of our announced growth capex plans Revenue in INR Crores at Base price of FY’21 Speciality, Nutrition & Others: 65% Acetyls: 35% Speciality, Nutrition & Others: 52% Acetyls: 48% Speciality, Nutrition & Others: 46% Acetyls: 54% 9,500 6,900 4,944 FY'22

  • In addition to this we would also have growth in revenue from existing facilities.

  •  Our journey started in 2018 with an objective to improve Business Excellence  Operational efficiency (18+ years experience)

  • Sustainability  Digitally Accelerated Contract Manufacturing Six Sigma Lean

  •  Removing process inefficiencies  Upgradation & Security enhancement of ERP  improve cost effectiveness TPM Process  Process Automation  Addressing process variation

  •  Employee Collaboration  Improve asset utilization

  • An initiative between CII & 100,000 students in preventive health care to Sustainable livelihood to mapping and disseminating Foundation recognize Jubilant Bhartiato improve

  • SDG: Key Achievements ESG Assessment • Safety Culture Transformation from Chola Risk services 2020-22 •

  • The Economic Times recognized JVL as India’s top company for Sustainability and CSR 2021Global chemical industry's EHS initiative & Ethical framework towards safe chemicals management and performance excellenceS&P Global for DJSI 2021:

Negative 18
  • The schedule may undergo change due to exigencies on the part of Investors/ Analysts/Company.

  • We witnessed significant increase in input costs Including energy costs, which was passed on partially during the quarter, impacting segment’s EBITDA margin.

  • Nutrition and Health Solutions business performance was impacted Speciality Chemicals 10.9 8.3 (24%) mainly due to spreading of Bird & Swine Flu in EU & US region Nutrition & Health Solutions 3.4 2.4 (29%) resulting into lower demand.

  • Speciality Chemicals 27.7% 16.8% - EBITDA at USD 19.96 Mn, is lower by 47%, mainly due to Chemical Nutrition & Health Solutions 15.9% 12.5% Intermediate EBITDA normalization.

  • Nutrition Margins were Chemical Intermediates 27.3% 12.1% impacted due to lower sale, while Speciality Margins were impacted Net Margin 14.7% 6.8% due to higher input costs which were passed on partially .

  • Geographical Revenue Split Q1’FY23 Industry End-Use Split - PAT declined by 53% YoY driven by lower EBITDA, as explained above.

  • Nutrition and Health Solutions business performance was impacted Speciality Chemicals 84 64 (24%) mainly due to spreading of Bird & Swine Flu in EU & US region Nutrition & Health Solutions 27 19 (29%) resulting into lower demand.

  • Speciality Chemicals 27.7% 16.8% - EBITDA at Rs 151 Crore is lower by 47%, mainly due to Chemical Nutrition & Health Solutions 15.9% 12.5%

  • Nutrition Margins were Chemical Intermediates 27.3% 12.1% impacted due to lower sale, while Speciality Margins were impacted Net Margin 14.7% 6.8% due to higher input costs which were passed on partially .

  • Industry End-Use Split - PAT declined by 53% YoY driven by lower EBITDA, as explained above.

  • Geographical Revenue Split Q1’FY23 Industry End-Use Split  Segment EBITDA & Margin was lower mainly due to unprecedented Domestic Sales Nutrition, 7% and sharp increase in input costs including energy cost, which was for International Consumption Industrial, 12% passed on partially during the quarter.

  • Geographical Revenue Split Q1’FY23 Industry End-Use Split  Segment EBITDA & Margin was lower mainly due to unprecedented Domestic Sales Nutrition, 7% and sharp increase in input costs including energy cost, which was for International Consumption Industrial, 12% passed on partially during the quarter.

  • FINANCIALHIGHLIGHTS Revenue 21.6 19.5 (10%)  Nutritional Business sales was impacted mainly due to spread of Bird Reported EBITDA 3.4 2.4 (29%)

  • Flu and Swine Flu in Europe US region, coupled with lower Reported EBITDA Margin (%) 15.9% 12.5% consumption in China due to covid related lock down situation.

  •  Niacinamide volumes were downby 39% YOY basis EBITDA  EBITDA de-grew by 29% on YoY basis and EBIDTA margin decreased to 12.5 % vs 15.9% in Q1’FY22 mainly due to lower volume, while price realization has been better.

  • Nutritional Business sales was impacted mainly due to spread of Bird Reported EBITDA 27 19 (29%)

  • Flu and Swine Flu in Europe US region, coupled with lower Reported EBITDA Margin (%) 15.9% 12.5% consumption in China due to covid related lock down situation.

  •  Niacinamide volumes were downby 39% YOY basis EBITDA  EBITDA de-grew by 29% on YoY basis and EBIDTA margin decreased to 12.5 % vs 15.9% in Q1’FY22 mainly due to lower volume, while price realization has been better.

Mentioned Phrases & Organizations

Important keywords detected (20+)

revenue (108)
usd (92)
yoy (84)
ebitda (80)
health (73)
chemicals (66)
basis (65)
segment (59)
grew (53)
intermediates (51)
sales (48)
domestic (42)
growth (42)
solutions (41)
results (40)
business (40)
margin (38)
million (38)
jubilant (35)
acetic (35)

Organizations identified (10+)

Speciality Chemicals (32)
Jubilant Pharmova Limited (13)
Jubilant Ingrevia Limited (7)
Ethyl Acetate (7)
Jubilant Ingrevia (6)
Fine Chemicals (4)
CDMO (3)
EBIDTA (3)
Highlights USD (3)
Chemical Intermediates (3)

Tables extracted (10)

BlackRock AsiaAMIRAL GESTIONNippon Offshore
White Oak CapitalSomerset CapitalVictory Capital
First State InvestmentsMaybank Asset Management Singapore Pte LtdDymon Asia
Goldman Sachs Asset ManagementAmansa Investment Advisors Pvt LtdTempleton Markets Group Emerging
• 2007-10 • Safety 2007 • M/s. • Based For more details, visit ourThe Economic Times recognized JVL as India’s top company for Sustainability and CSR 2021 Global chemical industry's EHS initiative & Ethical framework towards safe chemicals management and performance excellence S&P Global for DJSI 2021: Top 3 Indian Chemical companies in ESG 2019 2018 2016 2016 National Energy Conservation Award Logistics & Supply Chain Awards 2019 FICCI Safety Award FICCI Water Award FICCI Chemicals & Petrochemicals Awards CII Excellence in Energy Award2019 2018 2016 2016 National Energy Conservation Award Logistics & Supply Chain Awards 2019 FICCI Safety Award FICCI Water Award FICCI Chemicals & Petrochemicals Awards CII Excellence in Energy Award
C Rating 2021

Features are experimental.